TrialsgrambêtaRCTs are beautiful
AHA Scientific Sessions 2026Présenté sam. 7 nov. · 14:15 UTC−6LBS.02 Late-breaking Science: Treating the Clot or Controlling the Blood Pressure: Improving Outcomes After StrokeTous les essais Late-Breaking Science →

OPTIMAL-Stroke

2026

OPTIMAL-Stroke: Optimal Blood Pressure for the Prevention of Major Vascular Events in Stroke Patients

In adults with prior ischaemic stroke or TIA, an intensive systolic blood-pressure target reduced major cardiovascular events compared with a standard systolic target.

Résultat

Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalisation for unstable angina or heart failure
Différence absolue
2,6 points
Estimation de l’effet

about 21% less likely21

La différence absolue est dérivée des taux d’événements.

Également rapporté: To experience a major cardiovascular event. Recurrent stroke 4.7% vs 6.4%, driven by fewer ischaemic strokes. Serious adverse events were similar in both groups. Kidney-related events increased with intensive treatment.

Publication originale
Sous-thème
Intensive BP targets
Schéma
Pragmatic, multicentre randomised trial with blinded outcome assessment (Hospital Israelita Albert Einstein; 30 Brazilian sites); systolic target below 120 mmHg versus below 140 mmHg after ischaemic stroke or TIA, mean follow-up about 3.5 years
Inclus
4 368 patients
Source
Sampaio G. Presented at AHA Scientific Sessions 2026, 7 November. American Heart Association newsroom. Not yet published.

Discussion et critique

Intensive blood-pressure lowering reduced major cardiovascular events after ischaemic stroke or TIA over an average of 3.9 years, with fewer recurrent strokes driven by ischaemic events. The release gives event counts and a rough relative reduction but no hazard ratio, confidence interval or P value, so the size and precision of the effect cannot be judged from it. Not all patients in the intensive group reached their target, and kidney-related events were more common with intensive treatment, a harm whose size the release does not quantify. The trial was run at 30 centres in Brazil, and the investigators caution that the results may not apply where healthcare access differs.